How well does Truseltiq(Infigratinib) work?

In a clinical trial, TRUSELTIQ demonstrated an overall response rate of 23% in patients with FGFR2-altered cholangiocarcinoma.

Clinical Results

The efficacy of TRUSELTIQ was established in a single-arm clinical trial involving 108 patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. The blinded independent central review assessed an overall response rate (ORR) of 23%, which included a 1% complete response rate and a 22% partial response rate. The median duration of response (DoR) was 5.0 months, with 32% of responding patients maintaining their response for 6 months or longer. The median time to initial response was 3.6 months.